The microbiome already exists on the surface of our body, including the intestinal area, and is closely related to our health and disease. The administration of live microorganisms, such as probiotics or live biotherapeutics, may improve the health status or be used to treat diseases of the host, such as Clostridium difficile infection, irritable bowel disease, and colon cancer. The paper about CDI therapeutics that passed FDA 3rd trial is attached below.
The potential mechanisms of probiotics and LBPs on the host include immune regulation, as well as the ability to affect and interact with our body in various ways, such as pathogen inhibition and SCFA production.
Article SER-109, an Oral Microbiome Therapy for Recurrent Clostridio...